ArcherDX Blog



Dec
16
2016

From enhanced variant calling to immune repertoire analysis: Greater assay design and analytics with Archer software updates

In this webinar, Brent Lutz, Product Manager of Software, and Doug Wendel, Senior Director of Software, will detail new Assay Designer and Analysis features designed to leverage and maximize the unique power of the patented Anchored Multiplex PCR (AMP™) target enrichment chemistry used in Archer NGS assays. Their talk will cover: • Enhanced variant calling via error correction and multi-sample noise reduction • Immune repertoire analysis • Archer Quiver™ Fusion Database customization • REST API for robust workflow integration • Mix & match cached targets for simple and fast custom assays • Integration with third party reporting providers


Dec
5
2016

ArcherDX launches Immune Repertoire Sequencing Assays at ASH 2016

ArcherDX, the leader in NGS-based fusion assays, today announced the release of the Archer® Immunoverse™ immune repertoire sequencing assays. ArcherDX plans to reveal Immunoverse at the 58th American Society of Hematology Annual Meeting, which starts this weekend in San Diego, CA.


Dec
3
2016

Meet us at ASH 2016

Join us for the 2016 The American Society of Hematology (ASH) in San Diego, CA. By combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer is unleashing the power of translational NGS to enable mutation detection.


Nov
17
2016

ArcherDx Focuses on CDx and IVD Development Based on Patented Target Capture Tech

ArcherDx has been developing new products for cancer research and other applications over the past year and has established additional partnerships, including for companion diagnostic and in vitro diagnostic development. Last week, the company and its customers presented several posters at the American Molecular Pathology annual meeting on research involving many new assays. In addition, the firm was recently granted a US patent for its core technology, which enables open-ended capture of target sequences from a single primer for next-gen sequencing analysis.


Nov
14
2016

Anchored Multiplex PCR patent is issued to inventors at Massachusetts General Hospital

ArcherDX, the leader in next-generation sequencing (NGS)-based gene fusion detection products, announced today the issuance of the first patent for Anchored Multiplex PCR (AMP™), the technology that forms the foundation of the company’s products.


Nov
9
2016

Meet us at AMP 2016

Join us at the 2016 Association of Molecular Pathology Annual Meeting in Charlotte, North Carolina.


Oct
12
2016

ArcherDX at the Companion Diagnostics Symposium 2016

Join us at the 2016 Companion Diagnostics Symposium in Edison, NJ this November. By combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer® is unleashing the power of translational NGS to enable mutation detection.


Oct
11
2016

Why I work at ArcherDX

Erik Reckase describes his experiences on his journey to Archer, seeking a meaningful work environment where learning and collaboration is encouraged.


Oct
5
2016

Validation of the Archer® FusionPlex® Solid Tumor Panel in the JAX Cancer Treatment Profile™

This webinar outlines the clinical validation of the incorporation of the Archer® FusionPlex® Solid Tumor Panel (AFPSTP) into the JAX Cancer Treatment Profile™ (JAX-CTP) test system


Oct
7
2016

ArcherDX at the 2016 ESMO Congress

Join us at the ESMO Congress in Copenhagen, Denmark on 7-11 October, 2016. Combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer® unleashes the power of translational NGS to enable mutation detection.

How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2017 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.